Shopping Cart
Remove All
Your shopping cart is currently empty
Ocaratuzumab (AME-133v) is an Fc-engineered antibody and humanized monoclonal antibody targeting CD20 (Kd≈100 pM), exhibiting antibody-dependent cellular cytotoxicity (ADCC) in chronic lymphocytic leukemia.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $290 | - | In Stock | |
| 5 mg | $755 | - | In Stock | |
| 10 mg | $1,200 | - | In Stock |
| Description | Ocaratuzumab (AME-133v) is an Fc-engineered antibody and humanized monoclonal antibody targeting CD20 (Kd≈100 pM), exhibiting antibody-dependent cellular cytotoxicity (ADCC) in chronic lymphocytic leukemia. |
| In vitro | Ocaratuzumab (0.027-20 μg/mL) can concentration-dependently inhibit the binding of biotinylated Rituximab to CD20 on the surface of SKW6.4 cells [1]. |
| Synonyms | LY2469298, LY 2469298, Humanized Anti-MS4A1 Recombinant Antibody, AME133v, AME 133v |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Cas No. | 1169956-08-4 |
| Color | Transparent |
| Appearance | Liquid |
| Isotype | IgG1 |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.